Refine
Year of publication
Document Type
- Preprint (470)
- Article (399)
- Working Paper (2)
Language
- English (871)
Has Fulltext
- yes (871)
Is part of the Bibliography
- no (871)
Keywords
- BESIII (17)
- Heavy Ion Experiments (12)
- e +-e − Experiments (12)
- Branching fraction (9)
- Hadron-Hadron Scattering (8)
- Particle and Resonance Production (8)
- Quarkonium (6)
- Hadron-Hadron scattering (experiments) (5)
- Hadronic decays (5)
- Spectroscopy (5)
Institute
- Physik (824)
- Frankfurt Institute for Advanced Studies (FIAS) (523)
- Informatik (465)
- Informatik und Mathematik (4)
- Biodiversität und Klima Forschungszentrum (BiK-F) (1)
- Center for Financial Studies (CFS) (1)
- ELEMENTS (1)
- Georg-Speyer-Haus (1)
- House of Finance (HoF) (1)
- Institut für Ökologie, Evolution und Diversität (1)
The p300/CBP‐associated factor (PCAF) and related GCN5 bromodomain‐containing lysine acetyl transferases are members of subfamily I of the bromodomain phylogenetic tree. Iterative cycles of rational inhibitor design and biophysical characterization led to the discovery of the triazolopthalazine‐based L‐45 (dubbed L‐Moses) as the first potent, selective, and cell‐active PCAF bromodomain (Brd) inhibitor. Synthesis from readily available (1R,2S)‐(−)‐norephedrine furnished L‐45 in enantiopure form. L‐45 was shown to disrupt PCAF‐Brd histone H3.3 interaction in cells using a nanoBRET assay, and a co‐crystal structure of L‐45 with the homologous Brd PfGCN5 from Plasmodium falciparum rationalizes the high selectivity for PCAF and GCN5 bromodomains. Compound L‐45 shows no observable cytotoxicity in peripheral blood mononuclear cells (PBMC), good cell‐permeability, and metabolic stability in human and mouse liver microsomes, supporting its potential for in vivo use.